Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases
Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases
Not yet recruiting · NCT07051070 · Registry updated 2025-07-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases | Anti-Vimentin Antibody-associated Diseases; Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies | Not yet recruiting | Phase 4 | 2025-07-03 | NCT07051070 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Xuanwu Hospital, Beijing | 232 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Xuanwu Hospital, Capital Medical University | Beijing | China | 21 |